Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Giuseppa Sarobba(Azienda Ospedaliero Universitaria di Sassari), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Luca Moscetti(Ospedale di Belcolle), Paolo Carlini(National Cancer Institute), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Grazia Arpino(University of Naples Federico II), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giancarlo Bisagni, Alessio Aligi Cogoni(Azienda Ospedaliero Universitaria di Sassari), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, D. Amoroso(Ospedale Versilia), Antonio Russo(University of Palermo), F. Cognetti(Sapienza University of Rome), Lucio Laudadio(Ospedale "Floraspe Renzetti")
Cited by 4
Related Papers
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830